Last reviewed · How we verify

NCT06971965: MAeSTro-TSH

Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.

Not yet recruiting NA Last updated 14 May 2025
What this trial tests

NA trial testing Levothyroxin in Thyroid Cancer in 578 participants. Not yet recruiting.

Timeline
2 June 2025
Primary endpoint
31 December 2027
31 December 2032

Quick facts

Lead sponsorNational Cancer Center, Korea
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposehealth services research
Enrollment578
Start date2 June 2025
Primary completion31 December 2027
Estimated completion31 December 2032

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Center, Korea

Who can join

Adults 19 to 79, any sex, with Thyroid Cancer or Papillary Thyroid Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Levothyroxin

Trials testing the same drug.

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

Other National Cancer Center, Korea trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06971965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing